logo

Merus B.V. (MRUS)



Trade MRUS now with
  Date
  Headline
8/10/2018 8:39:11 AM Merus Q2 Total Revenue €6.5 Mln Vs. €6.2 Mln Prior Year
5/24/2018 7:05:40 AM Merus Announces First Patient Dosed In Phase 1 Trial Of MCLA-158 In Patients With Solid Tumors
4/30/2018 9:20:55 AM Wedbush Is Increasing Merus B.V. (MRUS) FY18 Estimate To -3.29 From -3.78
4/30/2018 9:20:41 AM Wedbush Is Increasing Merus B.V. (MRUS) Q4 18 Estimate To -0.94 From -1.07
4/30/2018 9:20:26 AM Wedbush Is Raising Merus B.V. (MRUS) Q3 18 Estimate To -0.86 From -0.98
4/30/2018 9:20:07 AM Wedbush Is Raising Merus B.V. (MRUS) Q2 18 Estimate To -0.78 From -0.90
4/30/2018 9:19:52 AM Wedbush Is Increasing Merus B.V. (MRUS) Q1 18 Estimate To -0.72 From -0.83
4/30/2018 9:19:07 AM Wedbush Reiterates Merus B.V. (MRUS) At Outperform With $26 Down From $32 Price Target
3/14/2018 7:11:31 AM Merus Announces Ono Exercised Its Option For New Research And License Agreement
3/13/2018 7:04:26 AM Merus Expands Intellectual Property Portfolio With Two Newly Issued U.S. Patents
1/26/2018 7:04:48 AM Merus Announces First Patient Dosed In A Phase 2 Clinical Trial Of MCLA-128 In Two MBC Patient Populations
1/12/2018 9:03:23 AM Wedbush Reiterates Merus B.V. (MRUS) At Outperform With $32 Price Target
1/8/2018 7:12:50 AM Merus, Simcere Announce Strategic Collaboration On Multiple Bispecific Antibodies
1/4/2018 7:05:35 AM Merus Announces Submission Of IND Application To FDA For MCLA-117
6/6/2017 1:52:37 PM Wedbush Reiterates Merus B.V. (MRUS) At Outperform With $32 Price Target
11/7/2016 11:52:43 AM Wedbush Is Raising Merus B.V. (MRUS) 2017 Estimate To -1.94 From -1.95
11/7/2016 11:52:17 AM Wedbush Is Cutting Merus B.V. (MRUS) Q4 17 Estimate To -0.57 From -0.56
11/7/2016 11:51:55 AM Wedbush Is Lowering Merus B.V. (MRUS) Q2 17 Estimate To -0.43 From -0.42
11/7/2016 11:51:35 AM Wedbush Is Increasing Merus B.V. (MRUS) Q1 17 Estimate To -0.45 From -0.48
11/7/2016 11:51:11 AM Wedbush Is Raising Merus B.V. (MRUS) 2016 Estimate To -1.75 From -1.88